<p>Spero Therapeutics, Inc.（納斯達克代碼：SPRO - 獲取免費報告）的股票在週五的交易中突破了其 200 日移動平均線。該股票的 200 日移動平均線為 2.16 美元，最高交易價為 2.33 美元。Spero Therapeutics 的股票最後交易價為 2.31 美元，成交量為 170,117 股。</p>
<p>獲取 <strong>Spero Therapeutics</strong> 的提醒：</p>
<h2>華爾街分析師觀點</h2>
<p>幾位研究分析師最近對 SPRO 股票進行了評估。Zacks Research 在 10 月 13 日的報告中將 Spero Therapeutics 的股票評級從 “強力買入” 下調至 “持有”。Weiss Ratings 在 10 月 8 日的報告中重新發布了對 Spero Therapeutics 的 “賣出（d-）” 評級。一位投資分析師給予該股票買入評級，兩位分析師給予持有評級，一位分析師給予賣出評級。根據 MarketBeat.com 的數據，Spero Therapeutics 目前的平均評級為 “持有”，共識目標價為 5.00 美元。</p>
<p><strong>閲讀我們對 SPRO 的最新股票分析</strong></p>
<h2>Spero Therapeutics 股票表現</h2>
<p>該公司的市值為 1.3015 億美元，市盈率為-2.92，貝塔值為 1.55。該公司的 50 日移動平均價格為 2.24 美元，200 日移動平均價格為 2.16 美元。</p>
<p>Spero Therapeutics（納斯達克代碼：SPRO - 獲取免費報告）最近在 11 月 13 日發佈了其財報。該公司報告本季度每股收益為（0.13 美元），超出分析師共識預期的（0.25 美元）0.12 美元。Spero Therapeutics 的淨利潤率為-108.11%，股本回報率為-125.91%。該公司本季度的收入為 544 萬美元，而分析師預期為 1200 萬美元。平均而言，股票分析師預測 Spero Therapeutics, Inc.在本年度將發佈-1.2 美元的每股收益。</p>
<h2>Spero Therapeutics 的內部買賣</h2>
<p>在其他消息中，內部人士 Esther Rajavelu 在 11 月 7 日的交易中出售了 40,270 股公司的股票。股票以平均價格 2.37 美元出售，總價值為 95,439.90 美元。出售後，該內部人士直接持有該公司 869,450 股股票，價值 2,060,596.50 美元。此次交易使其持股減少了 4.43%。該交易已在向 SEC 提交的文件中披露，文件可在 SEC 網站上獲取。公司內部人士目前持有 5.50% 的股票。</p>
<h2>機構投資者對 Spero Therapeutics 的看法</h2>
<p>大型投資者最近增加或減少了對該股票的持股。Mackenzie Financial Corp 在第一季度將其在 Spero Therapeutics 的持股增加了 11.4%。Mackenzie Financial Corp 現在擁有 209,031 股該公司的股票，價值 151,000 美元，此前在該期間購買了 21,472 股。Anson Funds Management LP 在第一季度將其在 Spero Therapeutics 的持股增加了 98.9%。Anson Funds Management LP 現在擁有 7,638,818 股該公司的股票，價值 5,500,000 美元，此前在上個季度購買了 3,798,932 股。Capital Asset Advisory Services LLC 在第二季度購買了 Spero Therapeutics 的新股份，價值 94,000 美元。Axxcess Wealth Management LLC 在第二季度購買了 Spero Therapeutics 的新股份，價值 94,000 美元。最後，XTX Topco Ltd 在第二季度購買了 Spero Therapeutics 的新股份，價值 100,000 美元。25.60% 的股票由機構投資者持有。</p>
<h2>Spero Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Spero Therapeutics, Inc.是一家臨牀階段的生物製藥公司，專注於識別、開發和商業化針對美國多重耐藥（MDR）細菌感染和罕見疾病的新治療方法。該公司的產品候選包括：用於治療複雜尿路感染（包括成人腎盂腎炎）的口服碳青黴烯類抗生素 tebipenem pivoxil hydrobromide（HBr）；針對多重耐藥革蘭陰性病原體的靜脈注射抗生素 SPR206，包括碳青黴烯耐藥腸桿菌（CRE）、鮑曼不動桿菌和銅綠假單胞菌，以及醫院環境中的陰性細菌感染；以及用於治療非結核分枝桿菌肺病的新型口服抗生素 SPR720。</p>
<h2>特色故事</h2>
<ul>
<li>我們更看好的五隻股票比 Spero Therapeutics 更好</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>一個輝煌的人工智能投資？Stanley Druckenmiller 的最新科技動態</li>
<li>Roth IRA 計算器：計算你的潛在回報</li>
<li>12 位分析師剛剛提高了 CrowdStrike 的目標價——他們預見了什麼</li>
<li>工業產品股票投資</li>
<li>Palo Alto Networks 的股票剛剛回調——這是一個理想的買入區嗎？</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Spero Therapeutics 嗎？</h2>
<p>在你考慮 Spero Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Spero Therapeutics 並不在名單上。</p>
<p>雖然 Spero Therapeutics 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

SPRO

<p>Spero Therapeutics（納斯達克代碼：SPRO）股票突破 200 日移動平均線，最高交易價格達到 2.33 美元。分析師的評級意見不一：Zacks 將評級下調至 “持有”，Weiss Ratings 則給出 “賣出” 評級，市場共識目標價為 5.00 美元。該公司報告的收益好於預期，但淨利潤率和股本回報率均為負值。內部交易和機構投資情況被提及，機構持股比例為 25.60%</p>

<p>Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $2.16 and traded as high as $2.33. Spero Therapeutics shares last traded at $2.31, with a volume of 170,117 shares trading hands.</p>
<div class="lb-trans"><p>Spero Therapeutics, Inc.（納斯達克代碼：SPRO - 獲取免費報告）的股票在週五的交易中突破了其 200 日移動平均線。該股票的 200 日移動平均線為 2.16 美元，最高交易價為 2.33 美元。Spero Therapeutics 的股票最後交易價為 2.31 美元，成交量為 170,117 股。</p>
</div><p>Get <strong>Spero Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Spero Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Several research analysts recently weighed in on SPRO shares. Zacks Research downgraded shares of Spero Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, October 13th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Spero Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Spero Therapeutics currently has an average rating of &#34;Hold&#34; and a consensus price target of $5.00.</p>
<div class="lb-trans"><p>幾位研究分析師最近對 SPRO 股票進行了評估。Zacks Research 在 10 月 13 日的報告中將 Spero Therapeutics 的股票評級從 “強力買入” 下調至 “持有”。Weiss Ratings 在 10 月 8 日的報告中重新發布了對 Spero Therapeutics 的 “賣出（d-）” 評級。一位投資分析師給予該股票買入評級，兩位分析師給予持有評級，一位分析師給予賣出評級。根據 MarketBeat.com 的數據，Spero Therapeutics 目前的平均評級為 “持有”，共識目標價為 5.00 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on SPRO</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 SPRO 的最新股票分析</strong></p>
</div><h2>Spero Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Spero Therapeutics 股票表現</h2>
</div><p>The firm has a market capitalization of $130.15 million, a PE ratio of -2.92 and a beta of 1.55. The company has a fifty day moving average price of $2.24 and a 200-day moving average price of $2.16.</p>
<div class="lb-trans"><p>該公司的市值為 1.3015 億美元，市盈率為-2.92，貝塔值為 1.55。該公司的 50 日移動平均價格為 2.24 美元，200 日移動平均價格為 2.16 美元。</p>
</div><p>Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.12. Spero Therapeutics had a negative net margin of 108.11% and a negative return on equity of 125.91%. The firm had revenue of $5.44 million during the quarter, compared to analyst estimates of $12.00 million. On average, equities analysts predict that Spero Therapeutics, Inc. will post -1.2 earnings per share for the current year.</p>
<div class="lb-trans"><p>Spero Therapeutics（納斯達克代碼：SPRO - 獲取免費報告）最近在 11 月 13 日發佈了其財報。該公司報告本季度每股收益為（0.13 美元），超出分析師共識預期的（0.25 美元）0.12 美元。Spero Therapeutics 的淨利潤率為-108.11%，股本回報率為-125.91%。該公司本季度的收入為 544 萬美元，而分析師預期為 1200 萬美元。平均而言，股票分析師預測 Spero Therapeutics, Inc.在本年度將發佈-1.2 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at Spero Therapeutics</h2>
<div class="lb-trans"><h2>Spero Therapeutics 的內部買賣</h2>
</div><p>In other news, insider Esther Rajavelu sold 40,270 shares of the business's stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $2.37, for a total value of $95,439.90. Following the sale, the insider directly owned 869,450 shares in the company, valued at $2,060,596.50. The trade was a 4.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 5.50% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他消息中，內部人士 Esther Rajavelu 在 11 月 7 日的交易中出售了 40,270 股公司的股票。股票以平均價格 2.37 美元出售，總價值為 95,439.90 美元。出售後，該內部人士直接持有該公司 869,450 股股票，價值 2,060,596.50 美元。此次交易使其持股減少了 4.43%。該交易已在向 SEC 提交的文件中披露，文件可在 SEC 網站上獲取。公司內部人士目前持有 5.50% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Spero Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Spero Therapeutics 的看法</h2>
</div><p>Large investors have recently added to or reduced their stakes in the stock. Mackenzie Financial Corp raised its position in Spero Therapeutics by 11.4% during the first quarter. Mackenzie Financial Corp now owns 209,031 shares of the company's stock valued at $151,000 after purchasing an additional 21,472 shares during the period. Anson Funds Management LP increased its position in shares of Spero Therapeutics by 98.9% during the 1st quarter. Anson Funds Management LP now owns 7,638,818 shares of the company's stock valued at $5,500,000 after purchasing an additional 3,798,932 shares during the last quarter. Capital Asset Advisory Services LLC purchased a new stake in Spero Therapeutics during the 2nd quarter valued at $94,000. Axxcess Wealth Management LLC bought a new stake in Spero Therapeutics in the second quarter worth $94,000. Finally, XTX Topco Ltd bought a new stake in Spero Therapeutics in the second quarter worth $100,000. 25.60% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>大型投資者最近增加或減少了對該股票的持股。Mackenzie Financial Corp 在第一季度將其在 Spero Therapeutics 的持股增加了 11.4%。Mackenzie Financial Corp 現在擁有 209,031 股該公司的股票，價值 151,000 美元，此前在該期間購買了 21,472 股。Anson Funds Management LP 在第一季度將其在 Spero Therapeutics 的持股增加了 98.9%。Anson Funds Management LP 現在擁有 7,638,818 股該公司的股票，價值 5,500,000 美元，此前在上個季度購買了 3,798,932 股。Capital Asset Advisory Services LLC 在第二季度購買了 Spero Therapeutics 的新股份，價值 94,000 美元。Axxcess Wealth Management LLC 在第二季度購買了 Spero Therapeutics 的新股份，價值 94,000 美元。最後，XTX Topco Ltd 在第二季度購買了 Spero Therapeutics 的新股份，價值 100,000 美元。25.60% 的股票由機構投資者持有。</p>
</div><h2>Spero Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Spero Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.</p>
<div class="lb-trans"><p>Spero Therapeutics, Inc.是一家臨牀階段的生物製藥公司，專注於識別、開發和商業化針對美國多重耐藥（MDR）細菌感染和罕見疾病的新治療方法。該公司的產品候選包括：用於治療複雜尿路感染（包括成人腎盂腎炎）的口服碳青黴烯類抗生素 tebipenem pivoxil hydrobromide（HBr）；針對多重耐藥革蘭陰性病原體的靜脈注射抗生素 SPR206，包括碳青黴烯耐藥腸桿菌（CRE）、鮑曼不動桿菌和銅綠假單胞菌，以及醫院環境中的陰性細菌感染；以及用於治療非結核分枝桿菌肺病的新型口服抗生素 SPR720。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than Spero Therapeutics</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li>
<li>Roth IRA Calculator: Calculate Your Potential Returns</li>
<li>12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming</li>
<li>Industrial Products Stocks Investing</li>
<li>Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Spero Therapeutics 更好</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>一個輝煌的人工智能投資？Stanley Druckenmiller 的最新科技動態</li>
<li>Roth IRA 計算器：計算你的潛在回報</li>
<li>12 位分析師剛剛提高了 CrowdStrike 的目標價——他們預見了什麼</li>
<li>工業產品股票投資</li>
<li>Palo Alto Networks 的股票剛剛回調——這是一個理想的買入區嗎？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Spero Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Spero Therapeutics 嗎？</h2>
</div><p>Before you consider Spero Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Spero Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spero Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Spero Therapeutics 並不在名單上。</p>
</div><p>While Spero Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Spero Therapeutics 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Spero Therapeutics（納斯達克股票代碼：SPRO）的股價突破了 200 日移動平均線 - 你應該賣出嗎？